This SCCOR application is designed to investigate the mechanisms involved in right ventricular dysfunction. It proposes a comprehensive dissection of phenotypes of pulmonary hypertension using an extensive population of idiopathic pulmonary arterial hypertension (IPAH) and scleroderma-associated PAH (PAH-SSc) to define novel genes involved in the disease and develop biomarkers related to disease morbidity and mortality. The Molecular Pathology Core (Core C) will provide high quality tissue processing, accurate phenotypic characterization of right ventricular and pulmonary vascular remodeling, and state-of-the art tools to investigate and validate potential markers of disease and pathogenetically relevant molecules that may play a role on the impact of pulmonary hypertension in right ventricular dysfunction in pulmonary hypertension. We propose the following strategies to accomplish these goals: 1. To assist the investigators in all projects in the experimental design to facilitate examine pulmonary vascular and right ventricular alterations in pulmonary hypertension (Projects 1-5);2. To collect, process, and catalogue human and animal lungs subjected to the different experimental manipulations, based on accrual of lungs obtained at the time of ex-plantation or lung tumor resection (Projects 1-3);3. To define the morphological alterations present in lung tissue to be subjected to genomic and proteomics studies (in sporadic biopsies or autopsies, in Projects 1-3);4. To perform immunohistochemical characterization of the pattern of lung distribution of markers and relevant proteins identified as important to the experiments outlined in Projects 1-5;5. To perform in situ hybridization strategies at the transcript localization in lungs (Projects 1-5);6. To correlate the protein and transcription data with morphological alterations present at the light microscopic level;and 7. To obtain cell and structure specific populations by laser micro-dissection for expression studies (Projects 1-5). Within the framework of discovery of biomarkers and genes associated with PAH, the Molecular Pathology Core will enable the validation of disease markers and candidate molecules in dysfunctional hearts and remodeled pulmonary arteries. Importantly, during the preparation of preliminary data for this proposal, this Core has demonstrated that its flexibility, expertise and resources are available and essential to all of the projects in the SCCOR proposal.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL084946-03
Application #
7802257
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
3
Fiscal Year
2009
Total Cost
$329,845
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hsu, Steven; Kokkonen-Simon, Kristen M; Kirk, Jonathan A et al. (2018) Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension. Circulation 137:2360-2370
Mercurio, Valentina; Mukherjee, Monica; Tedford, Ryan J et al. (2018) Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 197:388-391
Mecoli, Christopher A; Shah, Ami A; Boin, Francesco et al. (2018) Vascular complications in systemic sclerosis: a prospective cohort study. Clin Rheumatol 37:2429-2437
Yu, Bing; Pulit, Sara L; Hwang, Shih-Jen et al. (2016) Rare Exome Sequence Variants in CLCN6 Reduce Blood Pressure Levels and Hypertension Risk. Circ Cardiovasc Genet 9:64-70
Gao, Li; Emond, Mary J; Louie, Tin et al. (2016) Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. Arthritis Rheumatol 68:191-200
Hassoun, Paul M; Zamanian, Roham T; Damico, Rachel et al. (2015) Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 192:1102-10
Ohyama, Yoshiaki; Ambale-Venkatesh, Bharath; Chamera, Elzbieta et al. (2015) Comparison of strain measurement from multimodality tissue tracking with strain-encoding MRI and harmonic phase MRI in pulmonary hypertension. Int J Cardiol 182:342-348
Auer, Paul L; Nalls, Mike; Meschia, James F et al. (2015) Rare and Coding Region Genetic Variants Associated With Risk of Ischemic Stroke: The NHLBI Exome Sequence Project. JAMA Neurol 72:781-8
Parker, Sarah J; Raedschelders, Koen; Van Eyk, Jennifer E (2015) Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportions. Proteomics 15:1486-502
Damico, Rachel; Kolb, Todd M; Valera, Lidenys et al. (2015) Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 191:208-18

Showing the most recent 10 out of 108 publications